WO2006049234A1 - ペルオキシソーム増殖剤応答性受容体(ppar)活性化剤、ならびにそれを用いた医薬、サプリメント、機能性食品および食品添加物 - Google Patents
ペルオキシソーム増殖剤応答性受容体(ppar)活性化剤、ならびにそれを用いた医薬、サプリメント、機能性食品および食品添加物 Download PDFInfo
- Publication number
- WO2006049234A1 WO2006049234A1 PCT/JP2005/020268 JP2005020268W WO2006049234A1 WO 2006049234 A1 WO2006049234 A1 WO 2006049234A1 JP 2005020268 W JP2005020268 W JP 2005020268W WO 2006049234 A1 WO2006049234 A1 WO 2006049234A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ppar
- nobiletin
- activator
- insulin resistance
- hyperlipidemia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- PPAR Peroxisome proliferator-activated receptor
- the present invention relates to a peroxisome proliferator-activated receptor (PPAR) activator, and a medicament, supplement, functional food and food additive using the same.
- PPAR peroxisome proliferator-activated receptor
- PPAR which is a nuclear receptor
- PPARa is mainly expressed in liver cells and is also expressed in cardiomyocytes and gastrointestinal cells, and is involved in fatty acid oxidation, ketone body formation, and apolipoprotein production.
- PPAR ⁇ has no tissue specificity and is expressed throughout the body, but it is markedly expressed in colorectal cancer cells.
- PPAR ⁇ can be classified into two subtypes, ⁇ ⁇ type and ⁇ type 2.
- ⁇ type 1 is expressed in adipose tissue, immune system tissue, adrenal gland, and small intestine
- y type 2 is specific in adipocytes. It plays an important role in the induction of adipocyte differentiation and fat synthesis.
- PPAR is greatly involved in improving insulin resistance. It is said that it is also involved in the improvement of obesity, hypertension, hyperlipidemia and arteriosclerosis. From this point of view, research has been conducted on substances that activate PPAR. For example, fibrates, thiazolidine derivatives, fatty acids, leukotriene B4, indomethacin, ibuprofen, fenoprofen, 15-deoxy- ⁇ -1 2, 14-? 0: There are two known synthetic substances! ⁇ Activators. However, synthetic PPAR activators have problems of side effects due to long-term ingestion and are not suitable for preventing or improving diseases such as insulin resistance by taking them in daily life.
- Patent Document 1 Japanese Patent Laid-Open No. 2002-80362
- the present invention has been made in view of such circumstances, and provides a PPAR activator that can be taken for a long time without problems of side effects, and has no problem when added to food or the like. Objective.
- the PPAR activator of the present invention comprises nobiletin.
- the present inventor conducted a series of studies on a natural component PPAR activator, and as a result, citrus fruits, in particular, Shiki-kusha shrine (Official name: Citrus depressa HAYATA.) Of nobiletinka PPAR contained in fish The present invention has been found. In other words, siku-shah that contains a large amount of nobiletin has been eaten for many years, and its safety has been confirmed. In addition, nobiletin is low in calories and can be used for a long time by diabetics and obese patients.
- nobiletin is tasteless and odorless, even if it is added to food, etc., it does not impair the unique flavor of the food, so it can be added to food and taken daily for a long time. . Therefore, according to the present invention, activation of nobiletin PPAR promotes fat burning, suppresses secretion of TNF- ⁇ and free fatty acids, and promotes adiponectin secretion. Can improve insulin resistance, and other symptoms such as hyperinsulinemia, type 2 diabetes, hypertension, hyperlipidemia, arteriosclerosis and obesity. This is not limited to humans and is also effective for other animals.
- FIG. 1 is a graph showing the PAAR y ligand activity of nobiletin in an example of the present invention.
- FIG. 2 is a graph showing an increase in the expression level of adiponectin mRNA by nobiletin in other examples of the present invention.
- FIG. 3 is a graph showing the effect of nobiletin in improving diabetes in still another example of the present invention.
- the activated PPAR may be either PPAR a or PPA, but preferably both.
- the PPAR activator of the present invention may contain components other than nobiletin. Examples of the other components include various additives, and other PPAR activators other than nobiletin.
- the PPAR activator of the present invention is, for example, an inhibitory action on the secretion of TNF- ⁇ and free fatty acids in adipocytes, and adiponectin. It has the effect of promoting secretion and promoting ⁇ -oxidation of fat in liver cells.
- the PPAR activator of the present invention induces at least one of apoptosis, differentiation and miniaturization of adipocytes.
- nobiletin used is not particularly limited, but, for example, citrus-derived ones can be used, and those derived from shikushisha, known as offshore specialty fruits, are preferred. Since the fruit juice of shiikku-shah is rich in nobiletin, it can be used as it is, or it can be used as it is isolated and purified from citrus fruits or on the market.
- the medicament of the present invention is an insulin resistance, hyperinsulinemia, type 2 diabetes, hypertension, hyperlipidemia, arteriosclerosis and obesity group power of at least one disease selected
- a medicament for prevention or treatment, comprising the PPAR activator of the present invention comprising the PPAR activator of the present invention.
- the medicament of the present invention may contain, for example, other PPAR activators and various additives in addition to the PPAR activator of the present invention.
- Specific examples of the dosage form of the medicament of the present invention include tablets, fine granules (including powders), capsules and liquids (including syrups).
- the medicament of the present invention can be produced according to a conventional method described in the Japanese Pharmacopoeia or the like, using additives and base materials suitable for each dosage form as appropriate.
- the administration route is not particularly limited, and examples thereof include oral administration and parenteral administration.
- parenteral administration include oral administration, intratracheal administration, rectal administration, subcutaneous administration, Examples include intramuscular administration and intravenous administration.
- the dosage strength of nobiletin per day for example, nobiletin is preferably 20 mg or more as long as it contains nobiletin so as to be 10 mg or more.
- the supplement of the present invention comprises insulin resistance, hyperinsulinemia, type 2 diabetes, hypertension, hyperlipidemia, arteriosclerosis and obesity, or the prevention of at least one disease selected or A supplement for improvement comprising the PPAR active agent of the present invention.
- the supplement of the present invention may contain, for example, other PPAR activators, various additives, other supplements, etc. And various vitamins such as amino acids and oligosaccharides.
- the form of the supplement of the present invention is not particularly limited, and examples thereof include tablets, fine granules (including powders), capsules, and liquids (including syrups).
- the content of nobiletin is the same as that of the pharmaceutical.
- the functional food of the present invention comprises at least one disease selected from the group strength of insulin resistance, hyperinsulinemia, type 2 diabetes, hypertension, hyperlipidemia, arteriosclerosis and obesity. It is a functional food for preventing or improving the above-mentioned, which is a functional food containing the PPAR activator of the present invention.
- the functional food of the present invention may contain, for example, other PPAR active agents and various additives.
- the form of the functional food of the present invention is not particularly limited, and examples thereof include potatoes, confectionery, and functional beverages.
- the food additive of the present invention contains at least one disease selected from the group forces of insulin resistance, hyperinsulinemia, type 2 diabetes, hypertension, hyperlipidemia, arteriosclerosis and obesity. It is a food additive for preventing or ameliorating the above, and comprising the PPAR activator of the present invention.
- the food additive of the present invention may contain, for example, other PPAR active agents and various additives in addition to the PPAR active agent of the present invention.
- the form of the food additive of the present invention is not particularly limited, and examples thereof include liquid form, paste form, powder form, flake form, and granule form.
- the food additive of the present invention includes drinks.
- the PPAR activity method of the present invention is a method for activating PPAR with nobiletin. More preferably, the PPAR is activated by bringing the nobiletin into contact with, for example, a fat cell.
- the nobiletin used is the same as that used for the PPAR R activator of the present invention.
- those derived from citrus fruits can be used, and preferably It is derived from Shiikusu Shea, known as the offshore specialty fruit.
- the juice of shiikusu-shaya contains a large amount of nobiletin, so it can be used as it is, or it can be isolated and purified from citrus fruits or a commercial product.
- the method for preventing, treating or ameliorating a disease of the present invention comprises the following groups: insulin resistance, hyperinsulinemia, type 2 diabetes, hypertension, hyperlipidemia, arteriosclerosis and obesity in mammals.
- the daily dose of nobiletin is, for example, 10 mg / day or more, preferably 20 mgZ days or more.
- Examples thereof include humans, mice, rats, rabbits, dogs, cats, rabbits, horses, pigs, and monkeys.
- the kit of the present invention comprises at least one disease selected from the group forces of insulin resistance, hyperinsulinemia, type 2 diabetes, hypertension, hyperlipidemia, arteriosclerosis and obesity.
- a kit for prevention or treatment comprises at least one disease selected from the group forces of insulin resistance, hyperinsulinemia, type 2 diabetes, hypertension, hyperlipidemia, arteriosclerosis and obesity.
- a second compound useful for the prevention or treatment of at least one selected disease A second pharmaceutical composition comprising, and
- a kit comprising a container for containing the nobiletin and the second pharmaceutical composition.
- the use of the present invention is the use of nobiletin for the production of a PPAR activator.
- the use of the present invention is at least one selected from the group consisting of insulin resistance, hyperinsulinemia, type 2 diabetes, hypertension, hyperlipidemia, arteriosclerosis and obesity of the present invention in mammals.
- the daily dose of nobiletin and the mammal are as described above.
- the nobiletin used is the same as that used for the PPAR activator of the present invention, for example, those derived from citrus fruits, preferably known as offshore special fruit It is derived from shiikku shear. As described above, since a lot of nobiletin is contained in the fruit juice of Sikuikusha, it may be used as it is, or a citrus fruit isolated or purified product or a commercially available product may be used.
- nobiletin has effects such as suppression of secretion of TNF-a and free fatty acids in adipocytes, promotion of adiponectin secretion in adipocytes, and promotion of fat ⁇ -oxidation in liver cells. Guide at least one.
- nobiletin induces at least one of apoptosis, differentiation and miniaturization of adipocytes, for example.
- nobiletin in the present invention can be produced, for example, by squeezing from citrus fruits such as citrus shears as follows.
- the fruit is cut or crushed to a desired size.
- the fruit to be used may be a fresh product immediately after collection or a dried product.
- the cut fruit is immersed in a solvent to obtain an extract.
- the solvent used for the immersion include water, lower alcohols such as methanol, ethanol, n-propanol, isopropanol, and t-butanol, ketones such as acetone, ethers such as jetyl ether and petroleum ether, and chlorine.
- chlorinated organic solvents such as oral form and dichloromethane, and these may be used alone or in combination of two or more.
- the amount of the solvent used is not particularly limited, and is, for example, in the range of 200 parts by weight to 10 000 parts by weight with respect to 100 parts by weight of the fruit.
- the extraction treatment is, for example, a force that can be performed at room temperature, preferably in the range of 4 to 120 ° C, more preferably in the temperature condition of 40 to 100 ° C.
- the extraction time is appropriately determined depending on the extraction temperature or the like. For example, the extraction time at room temperature is 1 to 10 days, and 1 to 96 hours at 50 ° C. or higher.
- the extract is separated from the residue by filtration through a filter or the like. Since this extract or dried product thereof contains nobiletin, it may be used as it is. Further, as will be described later, it may be further purified to increase the purity of nobiletin.
- Purification of the extract can be performed, for example, by silica gel chromatography using an appropriate eluent.
- eluent for example, a mixed solvent of a solvent such as ethyl acetate, methanol, isopropyl ether, tetrahydrofuran, benzene, or xylene and a solvent such as hexane, heptane, chloroform, or dichloroethane is used. It is preferable to do.
- this Example is an example in which the activation of PPAR ⁇ by nobiletin was confirmed.
- CV-1 cells cultured cells derived from male African green monkey kidney
- DMEM Dulbecco, s Modified Eagle Medium: GIBCO
- FBS Ushi Fetal Serum
- lOmgZmL penicillin / streptomycin solution
- pM-hPPAR ⁇ and p4 X UASg-tk-luc were transfected into cultured CV-1 cells.
- the pM-hPPAR y is a vector for expressing a fusion protein comprising residues 1 to 147 which is a GAL4 binding domain and 204 to 505 residues which are a human PPAR y ligand binding domain.
- 4 11 8 3 8 — 1 ⁇ 11 ⁇ is a reporter plasmid containing an upstream active sequence (UAS) for the 4 copy GAL4 binding domain and a thymidine kinase gene promoter upstream of the luciferase gene.
- UAS upstream active sequence
- the transfected cells are cultured for about 24 hours, and then the medium of the cells is added to various concentrations (0.1, 1.0, 10 and 50 M) of nobiletin or an untreated control. The medium was changed and cultured for another 24 hours.
- the medium containing nobiletin was prepared by adding nobiletin dissolved in dimethyl sulfoxide (DMSO) to the medium, and the medium for the untreated control was prepared by calcining only DMSO. After culturing, the cells were lysed, and luciferase activity was measured using a dual luciferase reporter gene assembly system (Promega) (measurement group).
- DMSO dimethyl s
- nobiletin increased the activity of PPARy, and the activity increased significantly as the concentration of nobiletin increased.
- this example is an example of confirming the adiponectin secretion promoting effect by nobiletin.
- FBS usual fetal serum
- FBSZDMEM fetal serum
- a differentiation-inducing medium was prepared by adding MIX (3-Isobutyl-1 -methy lxanthine) (manufactured by Nacalai) to the medium in a necessary amount immediately before use so as to be 0.5 mM. MIX is very difficult to dissolve, so it was first dissolved in a small amount of 99.5% ethanol and then added to 10% FBSZDMEM. At this time, 99.5% ethanol was not allowed to exceed the final concentration force of 1%.
- MIX 3-Isobutyl-1 -methy lxanthine
- a differentiation promoting medium was prepared by adding 277.5 L of lOmgZmL insulin ZPBS to 555 mL of 10% FBS / DMEM.
- cultured preadipocytes 3T3-LI were thawed, seeded in 100 mm dishes, and cultured until 3T3-L1 force reached about 80% confluence.
- 10T1 / 2 of one dish that has reached about 80% confluence is passaged to one 6-well plate, and further cultured until 3T3-L1 reaches confluence in the 6-well plate, and then the medium is replaced with a differentiation-inducing medium. Then, differentiation was induced.
- the medium was removed from the 6-well plate, 1 mL of Sepazole RNA I super (manufactured by Nacalai) was added to each well, and the cells were dispersed by repeating pipetting several times. This solution was transferred to a 1.5 mL tube and allowed to stand at room temperature for 5 minutes. Then, the mouth-opening form was squeezed for 20 minutes! Stir well with Vortex and left at room temperature for 3 minutes. Cooled to 4 ° C and centrifuged at 12000 xg for 15 minutes. Taking care not to disturb the interface between the phenolic layer (lower layer, yellow) and the aqueous layer (upper layer, colorless), only the aqueous layer was transferred to another tube (capacity 1.5 mL).
- the tube was mixed with 500 L of isopropanol and allowed to stand at room temperature for 10 minutes. After cooling to 4 ° C and centrifuging at 12000 X g for 10 minutes, about 1 mL of the supernatant was removed. To this precipitate, 75 mL of ethanol was added and stirred, and the precipitate was sufficiently suspended. Then, the precipitate was cooled to 4 ° C., centrifuged at 12000 ⁇ g for 10 minutes, and the supernatant was removed. The obtained precipitate (total RNA) was dried, dissolved in 20 L of nuclease free water, and the mRNA concentration was measured by NanoDrop (manufactured by Scrum).
- the extracted and measured mRNA solution was prepared so that the mRNA concentration was: L gZ L.
- Oligo dT primer: LL and 10 L of the RNA solution were added to an 8 tube (capacity 0.2 mL). In the thermal cycler, incubate the above mixture at 70 ° C for 10 minutes, destroy the higher-order RNA structure, transfer it to ice, and leave it for more than 1 minute. Such reagents were added in order.
- the cap was capped with tweezers. After centrifuging at 5000 rpm and 4 ° C for 10 seconds, the capillary was loaded into the carousel, placed in the chamber, and measured.
- This example is an example of confirming the diabetes improving effect of nobiletin using spontaneously diabetic mice (KKA y ).
- adiponectin secretion by enzyme immunoassay was performed using the mouse ⁇ rat adiponectin ELISA kit (trade name) (manufactured by Otsuka Pharmaceutical Co., Ltd.).
- the configuration of the kit is as follows.
- Antibody plate anti-mouse adiponectin polyclonal antibody (usagi) solid phase plate) Standard 8. Ong / mL (recombinant mouse adiponectin)
- Piotin-labeled antibody solution (Piotin-labeled anti-mouse adiponectin polyclonal antibody ( Usagi))
- Substrate solution B hydrogen peroxide
- Purified water was mixed at a ratio of 960 mL to 40 mL of the washing stock solution and stored at 2.8 ° C.
- Purified water was mixed at a ratio of 200 mL to 50 mL of the specimen dilution stock solution, and stored at 2.8 ° C.
- the enzyme-labeled streptavidin stock solution was mixed at a ratio of 60 ⁇ L with 12 mL of the enzyme-labeled streptavidin dilution.
- the substrate solution A was mixed with 6 mL of the substrate solution B at a ratio of 6 mL.
- Body fluid
- the sera of the control group and the NOB group were diluted 40,000 times.
- N O B group 0 .2% 7 .1 8 ⁇ 0 .5 0
- adiponectin secretion in diabetic mice in the NOB group who took nobiletin and diabetic mice in the control group who did not take nobiletin adiponectin secretion in adipocytes due to ingestion of nobiletin The amount increased significantly.
- nobiletin has a diabetes-improving effect because it takes adiponectin secretion and promotes the secretion of adiponectin to bring the adipocyte state into a normal state and improve diabetes.
- the PPAR activator of the present invention has excellent PPAR activity and has a side effect. It can be taken for a long time without any problem, and can be preferably used for foods and the like. Nobiletin has an excellent adiponectin secretion promoting effect and the like. Therefore, the PPAR activator of the present invention is, for example, a medicament for preventing or ameliorating diseases such as insulin resistance, hyperinsulinemia, type 2 diabetes, hypertension, hyperlipidemia, arteriosclerosis and obesity, It can be used as a supplement, functional food and food additive. This is not limited to humans but is also effective for other animals.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006542437A JP5473191B2 (ja) | 2004-11-08 | 2005-11-04 | ペルオキシソーム増殖剤応答性受容体(ppar)活性化剤、ならびにそれを用いた医薬、サプリメント、機能性食品および食品添加物 |
EP05799960A EP1829542B1 (en) | 2004-11-08 | 2005-11-04 | Peroxisome proliferator-activated receptor (ppar) activator and drug, supplement, functional food and food additive using the same |
US11/800,637 US9573919B2 (en) | 2004-11-08 | 2007-05-07 | Peroxisome proliferator-activated receptor (PPAR) activator, and drugs, supplements, functional foods and food additives using the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004324015 | 2004-11-08 | ||
JP2004-324015 | 2004-11-08 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/800,637 Continuation-In-Part US9573919B2 (en) | 2004-11-08 | 2007-05-07 | Peroxisome proliferator-activated receptor (PPAR) activator, and drugs, supplements, functional foods and food additives using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006049234A1 true WO2006049234A1 (ja) | 2006-05-11 |
Family
ID=36319234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/020268 WO2006049234A1 (ja) | 2004-11-08 | 2005-11-04 | ペルオキシソーム増殖剤応答性受容体(ppar)活性化剤、ならびにそれを用いた医薬、サプリメント、機能性食品および食品添加物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9573919B2 (ja) |
EP (1) | EP1829542B1 (ja) |
JP (3) | JP5473191B2 (ja) |
CN (2) | CN104306367A (ja) |
WO (1) | WO2006049234A1 (ja) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008023262A2 (en) | 2006-08-24 | 2008-02-28 | Martinez Naranjo, Jhon, Jairo | System of brick with rod for retaining wall |
JP2008231024A (ja) * | 2007-03-20 | 2008-10-02 | Nagasakiken Koritsu Daigaku Hojin | 脂質代謝改善物、飲食品、および医薬品 |
KR100883356B1 (ko) | 2006-08-16 | 2009-02-11 | 제주대학교 산학협력단 | 비만 개선제 조성물 |
JP2011116696A (ja) * | 2009-12-03 | 2011-06-16 | Ushio Chemix Kk | ノビレチンの製造方法 |
WO2013099982A1 (ja) | 2011-12-26 | 2013-07-04 | 森永乳業株式会社 | 筋萎縮抑制剤 |
WO2014103410A1 (ja) | 2012-12-26 | 2014-07-03 | 森永乳業株式会社 | Igf-1産生促進剤 |
JP2015078140A (ja) * | 2013-10-15 | 2015-04-23 | 静岡県公立大学法人 | アルコール性脂肪肝予防・治療剤 |
JP2017178889A (ja) * | 2016-03-31 | 2017-10-05 | チズBeファクトリー株式会社 | Oph活性増強剤 |
JP2019023176A (ja) * | 2017-07-25 | 2019-02-14 | 沖縄県農業協同組合 | 転写因子活性促進剤および転写因子活性促進用食品組成物 |
WO2019182032A1 (ja) | 2018-03-22 | 2019-09-26 | 花王株式会社 | ノビレチン含有固体分散体の製造方法 |
US11160782B2 (en) | 2016-08-04 | 2021-11-02 | Kao Corporation | Method for producing nobiletin-containing solid dispersion |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1829542B1 (en) * | 2004-11-08 | 2012-07-18 | ARKRAY, Inc. | Peroxisome proliferator-activated receptor (ppar) activator and drug, supplement, functional food and food additive using the same |
JP2009506057A (ja) * | 2005-08-23 | 2009-02-12 | ウェルゲン、インコーポレイテッド | 脂肪細胞の脂肪蓄積を管理する方法 |
EP2434010A4 (en) * | 2009-05-22 | 2013-02-27 | Erina Co Inc | PREVENTIVE AND / OR THERAPEUTIC AGENT FOR THE METABOLIC SYNDROME |
JP2012056938A (ja) * | 2010-08-11 | 2012-03-22 | Japan Royal Jelly Co Ltd | ノビレチンの製造方法およびノビレチン含有抽出物 |
US9132117B2 (en) | 2013-06-17 | 2015-09-15 | Kgk Synergize, Inc | Compositions and methods for glycemic control of subjects with impaired fasting glucose |
US20160082066A1 (en) * | 2014-09-24 | 2016-03-24 | Vladimir Badmaev | Method Use of Polymethoxyflavones (PMFs) in Body Composition Management |
US10772863B2 (en) | 2016-03-15 | 2020-09-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Methods of inducing metabolic maturation of human pluripotent stem cells— derived hepatocytes |
JP6238089B1 (ja) * | 2016-06-01 | 2017-11-29 | 株式会社三協ホールディングス | 医薬組成物および食品 |
CN106310173A (zh) * | 2016-08-24 | 2017-01-11 | 厦门三川利生物科技有限公司 | 含过氧化物酶体增殖物激活受体多维果酸醇及其制备方法 |
CN107496407A (zh) * | 2017-09-14 | 2017-12-22 | 上海壹志医药科技有限公司 | 川陈皮素的药物用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000247880A (ja) | 1999-02-26 | 2000-09-12 | Nagase & Co Ltd | 脂肪分解促進剤 |
JP2001240539A (ja) * | 2000-03-02 | 2001-09-04 | Machida & Machida Shokai:Kk | 血圧上昇または血糖上昇を抑制するための薬剤または機能性食品 |
JP2002080362A (ja) | 2000-06-21 | 2002-03-19 | Kao Corp | Ppar依存的遺伝子転写活性化剤 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2305665C (en) * | 1997-08-29 | 2011-12-06 | The Ricex Company, Inc. | A method for treating diabetes, hyperglycemia and hypoglycemia |
JP3010210B1 (ja) * | 1998-09-02 | 2000-02-21 | 農林水産省果樹試験場長 | マトリックスメタロプロテアーゼ産生阻害剤 |
JP4633897B2 (ja) * | 2000-08-17 | 2011-02-16 | 長瀬産業株式会社 | 神経突起伸長剤 |
WO2002055071A1 (en) | 2001-01-15 | 2002-07-18 | Kgk Synergize | Compositions and methods for regulating lipoproteins and hypercholesterolmia with limonoids flavonoids and tocotrienols |
MXPA03010080A (es) * | 2001-05-02 | 2006-04-05 | Kgk Synergize Inc | Uso de flavonas polimetoxiladas para tratar la resistencia a la insulina. |
KR20050035142A (ko) * | 2001-10-11 | 2005-04-15 | 카네카 코포레이션 | 페록시좀 증식제 응답성 수용체 리간드제 및 그 제조 방법 |
CA2474964C (en) | 2002-01-31 | 2012-05-15 | Japan Science And Technology Agency | An insulin improving agent containing adiponectin |
JP4325908B2 (ja) * | 2002-10-18 | 2009-09-02 | 長瀬産業株式会社 | 脂肪分解促進剤ならびにそれを用いた皮膚外用剤および飲食物 |
EP1829542B1 (en) * | 2004-11-08 | 2012-07-18 | ARKRAY, Inc. | Peroxisome proliferator-activated receptor (ppar) activator and drug, supplement, functional food and food additive using the same |
-
2005
- 2005-11-04 EP EP05799960A patent/EP1829542B1/en active Active
- 2005-11-04 CN CN201410429281.2A patent/CN104306367A/zh active Pending
- 2005-11-04 JP JP2006542437A patent/JP5473191B2/ja active Active
- 2005-11-04 CN CNA2005800367293A patent/CN101052391A/zh active Pending
- 2005-11-04 WO PCT/JP2005/020268 patent/WO2006049234A1/ja active Application Filing
-
2007
- 2007-05-07 US US11/800,637 patent/US9573919B2/en active Active
-
2013
- 2013-05-13 JP JP2013101529A patent/JP2013163685A/ja active Pending
- 2013-05-13 JP JP2013101528A patent/JP2013163684A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000247880A (ja) | 1999-02-26 | 2000-09-12 | Nagase & Co Ltd | 脂肪分解促進剤 |
JP2001240539A (ja) * | 2000-03-02 | 2001-09-04 | Machida & Machida Shokai:Kk | 血圧上昇または血糖上昇を抑制するための薬剤または機能性食品 |
JP2002080362A (ja) | 2000-06-21 | 2002-03-19 | Kao Corp | Ppar依存的遺伝子転写活性化剤 |
Non-Patent Citations (2)
Title |
---|
KUROWSKA E.M.: "Modulation of HepG2 cell net apolipoprotein B secretion by the citrus polymethoxyflavone, tangeretin", LIPIDS, vol. 39, no. 2, February 2004 (2004-02-01), pages 143 - 151, XP002994811 * |
See also references of EP1829542A4 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100883356B1 (ko) | 2006-08-16 | 2009-02-11 | 제주대학교 산학협력단 | 비만 개선제 조성물 |
WO2008023262A2 (en) | 2006-08-24 | 2008-02-28 | Martinez Naranjo, Jhon, Jairo | System of brick with rod for retaining wall |
JP2008231024A (ja) * | 2007-03-20 | 2008-10-02 | Nagasakiken Koritsu Daigaku Hojin | 脂質代謝改善物、飲食品、および医薬品 |
JP2011116696A (ja) * | 2009-12-03 | 2011-06-16 | Ushio Chemix Kk | ノビレチンの製造方法 |
KR20140105860A (ko) | 2011-12-26 | 2014-09-02 | 모리나가 뉴교 가부시키가이샤 | 근위축 억제제 |
WO2013099982A1 (ja) | 2011-12-26 | 2013-07-04 | 森永乳業株式会社 | 筋萎縮抑制剤 |
US9492424B2 (en) | 2011-12-26 | 2016-11-15 | Morinaga Milk Industry Co., Ltd. | Muscle atrophy inhibitor |
WO2014103410A1 (ja) | 2012-12-26 | 2014-07-03 | 森永乳業株式会社 | Igf-1産生促進剤 |
JPWO2014103410A1 (ja) * | 2012-12-26 | 2017-01-12 | 森永乳業株式会社 | Igf−1産生促進剤 |
JP2015078140A (ja) * | 2013-10-15 | 2015-04-23 | 静岡県公立大学法人 | アルコール性脂肪肝予防・治療剤 |
JP2017178889A (ja) * | 2016-03-31 | 2017-10-05 | チズBeファクトリー株式会社 | Oph活性増強剤 |
US11160782B2 (en) | 2016-08-04 | 2021-11-02 | Kao Corporation | Method for producing nobiletin-containing solid dispersion |
JP2019023176A (ja) * | 2017-07-25 | 2019-02-14 | 沖縄県農業協同組合 | 転写因子活性促進剤および転写因子活性促進用食品組成物 |
WO2019182032A1 (ja) | 2018-03-22 | 2019-09-26 | 花王株式会社 | ノビレチン含有固体分散体の製造方法 |
US11236060B2 (en) | 2018-03-22 | 2022-02-01 | Kao Corporation | Method for producing solid dispersion containing nobiletin |
Also Published As
Publication number | Publication date |
---|---|
US20070213282A1 (en) | 2007-09-13 |
US9573919B2 (en) | 2017-02-21 |
JPWO2006049234A1 (ja) | 2008-05-29 |
EP1829542B1 (en) | 2012-07-18 |
CN104306367A (zh) | 2015-01-28 |
EP1829542A4 (en) | 2009-05-27 |
EP1829542A1 (en) | 2007-09-05 |
JP5473191B2 (ja) | 2014-04-16 |
JP2013163684A (ja) | 2013-08-22 |
JP2013163685A (ja) | 2013-08-22 |
CN101052391A (zh) | 2007-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5473191B2 (ja) | ペルオキシソーム増殖剤応答性受容体(ppar)活性化剤、ならびにそれを用いた医薬、サプリメント、機能性食品および食品添加物 | |
JP2014122247A (ja) | ペルオキシソーム増殖剤応答性受容体(ppar)活性化剤、ならびにそれを用いた医薬、サプリメント、機能性食品および食品添加物 | |
JP5004153B2 (ja) | アディポネクチン産生促進剤 | |
KR20120023787A (ko) | 대사증후군의 예방제 및/또는 치료제 | |
WO2007132893A1 (ja) | Mcp-1の発現抑制剤、それを用いた炎症性疾患の改善剤、医薬品、サプリメント、食品、飲料および食品添加剤 | |
JP5080813B2 (ja) | メタボリックシンドローム改善剤、ならびにそれを含む医薬、サプリメント、機能性食品および食品添加物 | |
JP5064036B2 (ja) | メタボリックシンドローム改善剤、ならびにそれを含む医薬、サプリメント、機能性食品および食品添加物 | |
JP2011063542A (ja) | アディポネクチン増加剤 | |
JP2006096666A (ja) | 選択的ヒトβ3アドレナリン受容体アゴニスト剤 | |
JP2007039367A (ja) | 細胞の分化を促進する組成物およびその利用 | |
JP2005075749A (ja) | 細胞分化促進剤 | |
JPWO2004045632A1 (ja) | ペルオキシソーム増殖剤応答性受容体リガンド剤 | |
JP2010189291A (ja) | アディポネクチン増加剤 | |
JP2011063543A (ja) | アディポネクチン増加剤 | |
JP2009114138A (ja) | コレステロール上昇抑制剤 | |
JP5346624B2 (ja) | Ppar活性化剤 | |
Lee et al. | The anti-obesity effects of Gambi-hwan extract on obese rats induced by high-fat diet through the expression of UCP-1 and PPAR-δ | |
JP6859128B2 (ja) | エピテアフラガリン類を利用したレプチン分泌促進剤 | |
JP2013095678A (ja) | Pparリガンド剤 | |
TW202227114A (zh) | Tgr5活化用組成物 | |
JP2019189598A (ja) | アディポネクチン受容体作動薬及びその使用、並びにアディポネクチン受容体作動用食品組成物及びその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006542437 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580036729.3 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11800637 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005799960 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005799960 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11800637 Country of ref document: US |